Ferring Patent-Cliff Exposure & CMS Drug Spending Portfolio
Ferring (US): 7 reconciled FDA prescription therapies, $42.9M 2024 CMS Part D & Medicaid spend, and $395 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 7 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2032-01-01 |
| 2024 CMS Total Public Spend | $42.9M |
| 2024 Medicare Part D Spend | $20.1M |
| 2024 Medicaid Spend | $22.9M |
| California HCAI SB 17 Filings | Specialty launch notice ($395 intro WAC) |